无标题文档

Cellular & Molecular Immunology. 2004 Apr, Vol.1, No.2, pp.153-157.
The Inhibitory Effects of Mouse ICOS-Ig Gene-Modified Mouse Dendritic Cells on T Cells

Guohua Wang¹, Lijuan Zhu², Ping Hu ², Huifen Zhu², Ping Lei², Wenjun Liao², Bing Yu², Feili Gong² and Guanxin Shen^{2, 3}

¹Institute of Biochemistry and Molecular Biology, Hubei University, Wuhan 430062, China.
2Department of Immunology, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China.
3Corresponding to: Dr. Guanxin Shen, Department of Immunology, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China. Tel: +86-27-83692640, Fax: +86-27-83693500, E-mail: myjsz@mails.tjmu.edu.cn.

The main approach to reduce graft rejection has been focused on the development of immunosuppressive agents at present. Although these strategies have reportedly reduced graft rejection, there has been a reciprocal increase in more severe immunosuppression and lethal infections, as well as severe side effects. Blockade of costimulatory T cell response has been proved as one of useful strategies to reduce graft rejection. Furthermore, it has been shown that infusion of dendritic cells (DCs) with a potent negative regulatory ability for T cells could prolong allograft survival. In this study mouse DCs (mDCs) were transfected with the recombinant plasmid pcDNA3.0 containing mouse inducible costimulator-Ig (mICOS-Ig) cDNA by electroporation. The transient expression of mICOS-Ig in mDC could be detected by ELISA and SDS-PAGE. Mouse ICOS-Ig fusion protein expressed in mDC and mICOS-Ig gene-modified mDC could inhibit lymphocyte proliferation in mixed lymphocyte culture (MLC) in vitro. Furthermore, mICOS-Ig gene-modified mDC could inhibit lymphocyte proliferation in recipient mice. These results suggested that mICOS-Ig gene-modified mDC exerted inhibitory effects on T cells, and might be suitable for treatment or prevention of graft rejection and immunopathologic diseases.